Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMO-2125 plus ipilimumab vs ipilimumab in anti-PD-1 refractory melanoma
2017-002454-36Phase 3Terminated
- Sponsor
- Aceragen, Inc.
- Start
- Mar 2018
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of tilsotolimod in melanoma (2 arms), sponsored by Aceragen, Inc. Started Mar 2018; status: terminated.
02
Drugs
tilsotolimod
03
Conditions
melanoma
Beyond the preview
Go deeper on 2017-002454-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002454-36.